Targets for molecular therapy in esophageal squamous cell carcinoma: An immunohistochemical analysis

Diseases of the Esophagus

Volumn 22, Issue 6, 2009, Pages 496-504

  Boone, Judith ^a   van Hillegersberg, R ^a   Offerhaus, G J A ^a   van Diest, P J ^a   Borel Rinkes, I H M ^a   ten Kate, F J W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Esophageal cancer; Immunohistochemistry; Molecular therapy; Squamous cell carcinoma; Targeted therapy; Tissue microarray

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; STEM CELL FACTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TISSUE MICROARRAY; TUMOR VOLUME;

CARCINOMA, SQUAMOUS CELL; CYCLIN D1; CYCLOOXYGENASE 2; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; PROTEIN ARRAY ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 69249123371     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.00951.x     Document Type: Article

References (67)

1. Kamangar F, Dores G M, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
2. Mariette C, Piessen G, Triboulet J P. Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol 2007; 8: 545-53.
3. Omloo J M, Lagarde S M, Hulscher J B et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: Five-year survival of a randomized clinical trial. Ann Surg 2007; 246: 992-1000.
4. Hulscher J B, van Sandick J W, Tijssen J G, Obertop H, Van Lanschot J J. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg 2000; 191: 143-8.
5. Gebski V, Burmeister B, Smithers B M, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007; 8: 226-34.
6. Vahid B, Marik P E. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133: 528-38.
7. Haddad T C, Greeno E W. Chemotherapy-induced thrombosis. Thromb Res 2006; 118: 555-68.
8. Lin C C, Papadopoulos K P. Novel targeted therapies for advanced esophageal cancer. Dis Esophagus 2007; 20: 365-71.
9. Smith I, Procter M, Gelber R D et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007; 369: 29-36.
10. Piccart-Gebhart M J, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 20 (353): 1659-72.
11. Romond E H, Perez E A, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 20 (353): 1673-84.
12. Hicks D G, Kulkarni S. HER2+ breast cancer: Review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 2008; 129: 263-73.
13. Valverde C M, Macarulla T, Casado E, Ramos F J, Martinelli E, Tabernero J. Novel targets in gastric and esophageal cancer. Crit Rev Oncol Hematol 2006; 59: 128-38.
14. Tew W P, Kelsen D P, Ilson D H. Targeted therapies for esophageal cancer. Oncologist 2005; 10: 590-601.
15. Schrump D S, Nguyen D M. Novel molecular targeted therapy for esophageal cancer. J Surg Oncol 2005; 92: 257-61.
16. Aklilu M, Ilson D H. Targeted agents and esophageal cancer - the next step? Semin Radiat Oncol 2007; 17: 62-9.
17. van Diest P J. No consent should be needed for using leftover body material for scientific purposes. BMJ 2002; 325: 648-51.
18. Boone J, van Hillegersberg R, Van Diest P J, Offerhaus G J A, Borel Rinkes I H M, Ten Kate F J W. Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Archiv 2008; 452: 507-14.
19. Gown A M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008; 21 (Suppl 2): S8-15.
20. Sivula A, Buskens C J, van Rees B P et al. Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int J Cancer 2005; 116: 903-8.
21. Utsumi Y, Nakamura T, Nagasue N, Kubota H, Morikawa S. Role of estrogen receptors in the growth of human esophageal carcinoma. Cancer 1989; 64: 88-93.
22. Utsumi Y, Nakamura T, Nagasue N, Kubota H, Harada T, Morikawa S. Effect of 17 beta-estradiol on the growth of an estrogen receptor-positive human esophageal carcinoma cell line. Cancer 1991; 67: 2284-9.
23. Ueo H, Matsuoka H, Sugimachi K, Kuwano H, Mori M, Akiyoshi T. Inhibitory effects of estrogen on the growth of a human esophageal carcinoma cell line. Cancer Res 1990; 50: 7212-5.
24. Kalayarasan R, Ananthakrishnan N, Kate V, Basu D. Estrogen and progesterone receptors in esophageal carcinoma. Dis Esophagus 2008; 21: 298-303.
25. Sato S, Kajiyama Y, Sugano M etal. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 2005; 61: 203-11.
26. Aloia T A, Harpole D H, Reed C E et al. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001; 72: 859-66.
27. Kawaguchi Y, Kono K, Mimura K et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007; 20 (97): 494-501.
28. Mimura K, Kono K, Hanawa M et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005; 92: 1253-60.
29. Gibault L, Metges J P, Conan-Charlet V et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 2005; 93: 107-15.
30. Safran H, Dipetrillo T, Akerman P et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 405-9.
31. Danial N N. BCL-2 family proteins: Critical checkpoints of apoptotic cell death. Clin Cancer Res 2007; 13: 7254-63.
32. Letai A. BCL-2: Found bound and drugged!. Trends Mol Med 2005; 11: 442-4.
33. Chi K N. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol 2005; 23: 33-7.
34. Nahta R, Esteva F J. Bcl-2 antisense oligonucleotides: A potential novel strategy for the treatment of breast cancer. Semin Oncol 2003; 30: 143-9.
35. Herbst R S, Frankel S R. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 2004; 10: 4245s-8s.
36. Prabhudesai S G, Rekhraj S, Roberts G, Darzi A W, Ziprin P. Apoptosis and chemo-resistance in colorectal cancer. J Surg Oncol 2007; 96: 77-88.
37. Hsia J Y, Chen C Y, Hsu C P et al. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma 2001; 48: 483-8.
38. Kurabayashi A, Furihata M, Matsumoto M, Ohtsuki Y, Sasaguri S, Ogoshi S. Expression of Bax and apoptosis-related proteins in human esophageal squamous cell carcinoma including dysplasia. Mod Pathol 2001; 14: 741-7.
39. Azmi S, Dinda A K, Chopra P, Chattopadhyay T K, Singh N. Bcl-2 expression is correlated with low apoptotic index and associated with histopathological grading in esophageal squamous cell carcinomas. Tumour Biol 2000; 21: 3-10.
40. Bedikian A Y, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738-45.
41. Alao J P. The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007; 6: 24.
42. Roy P G, Thompson A M. Cyclin D1 and breast cancer. The Breast 2006; 15: 718-27.
43. Diehl J A. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002; 1: 226-31.
44. Schrump D S, Matthews W, Chen G A, Mixon A, Altorki N K. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 1998; 4: 2885-90.
45. Raju U, Ariga H, Koto M et al. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiother Oncol 2006; 80: 185-91.
46. Sato S, Kajiyama Y, Sugano M, Iwanuma Y, Tsurumaru M. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Dis Esophagus 2004; 17: 338-44.
47. Hanawa M, Suzuki S, Dobashi Y et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 1173-80.
48. Syrigos K N, Zalonis A, Kotteas E, Saif M W. Targeted therapy for oesophageal cancer: An overview. Cancer Metastasis Rev 2008; 27: 273-88.
49. Sutter A P, Hopfner M, Huether A, Maaser K, Scherubl H. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 2006; 118: 1814-22.
50. Janmaat M L, Gallegos-Ruiz M I, Rodriguez J A etal. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24: 1612-9.
51. O'Reilly M S. Antiangiogenesis and vascular endothelial growth factor/ vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2007; 69: S64-6.
52. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
53. Sandler A, Gray R, Perry M C et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
54. Kleespies A, Guba M, Jauch K W, Bruns C J. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004; 87: 95-104.
55. Kase S, Osaki M, Honjo S et al. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2004; 23: 301-7.
56. Yu H P, Shi L Y, Lu W H, Su Y H, Li Y Y, Xu S Q. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J Gastroenterol Hepatol 2004; 19: 638-42.
57. Zhi H, Wang L, Zhang J et al. Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis 2006; 27: 1214-21.
58. Liu J F, Zhang S W, Jamieson G G et al. The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo. Int J Cancer 2008; 122: 1639-44.
59. Limburg P J, Wei W, Ahnen D J et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 2005; 129: 863-73.
60. Arber N, Eagle C J, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.
61. Bertagnolli M M, Eagle C J, Zauber A G et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-84.
62. Solomon S D, McMurray J J, Pfeffer M A et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
63. Heath E I, Canto M I, Piantadosi S et al. Secondary chemoprevention of Barrett's esophagus with celecoxib: Results of a randomized trial. J Natl Cancer Inst 2007; 99: 545-57.
64. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
65. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006; 11: 1010-7.
66. Siewert J R, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007; 17: 38-44.
67. Mariette C, Finzi L, Piessen G, Van S I, Triboulet J P. Esophageal carcinoma: Prognostic differences between squamous cell carcinoma and adenocarcinoma. World J Surg 2005; 29: 39-45.